EA200201175A1 - Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза - Google Patents

Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза

Info

Publication number
EA200201175A1
EA200201175A1 EA200201175A EA200201175A EA200201175A1 EA 200201175 A1 EA200201175 A1 EA 200201175A1 EA 200201175 A EA200201175 A EA 200201175A EA 200201175 A EA200201175 A EA 200201175A EA 200201175 A1 EA200201175 A1 EA 200201175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
atherosclerosis
prevention
treatment
inhibitors
medicament
Prior art date
Application number
EA200201175A
Other languages
English (en)
Other versions
EA005410B1 (ru
Inventor
Йоланд Шватшко
Алан Тедги
Зиад Маллат
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Энсэрм - Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В., Энсэрм - Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200201175A1 publication Critical patent/EA200201175A1/ru
Publication of EA005410B1 publication Critical patent/EA005410B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретение относится к применению ингибитора IL-18 для получения лекарственного средства для лечения и/или предотвращения атеросклероза.Отчет о международном поиске был опубликован 2002.05.10.
EA200201175A 2000-05-05 2001-04-30 Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза EA005410B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (2)

Publication Number Publication Date
EA200201175A1 true EA200201175A1 (ru) 2003-04-24
EA005410B1 EA005410B1 (ru) 2005-02-24

Family

ID=8168631

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200201175A EA005410B1 (ru) 2000-05-05 2001-04-30 Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
EA200401183A EA007014B1 (ru) 2000-05-05 2001-04-30 Применение il-18 в качестве диагностического маркера

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200401183A EA007014B1 (ru) 2000-05-05 2001-04-30 Применение il-18 в качестве диагностического маркера

Country Status (33)

Country Link
US (1) US20040076628A1 (ru)
EP (1) EP1278540B1 (ru)
JP (1) JP5122053B2 (ru)
KR (2) KR100798545B1 (ru)
CN (2) CN1841066B (ru)
AR (1) AR035640A1 (ru)
AT (1) ATE395075T1 (ru)
AU (2) AU6739001A (ru)
BG (1) BG65881B1 (ru)
BR (1) BRPI0110506B8 (ru)
CA (1) CA2407895C (ru)
CY (1) CY1110385T1 (ru)
CZ (1) CZ300792B6 (ru)
DE (1) DE60134009D1 (ru)
DK (1) DK1278540T3 (ru)
EA (2) EA005410B1 (ru)
EE (1) EE05056B1 (ru)
ES (1) ES2305082T3 (ru)
HK (2) HK1055681A1 (ru)
HR (1) HRP20020828A2 (ru)
HU (1) HU229375B1 (ru)
IL (2) IL152567A0 (ru)
ME (1) ME00554B (ru)
MX (1) MXPA02010895A (ru)
NO (1) NO329821B1 (ru)
PL (1) PL209371B1 (ru)
PT (1) PT1278540E (ru)
RS (1) RS50926B (ru)
SI (1) SI1278540T1 (ru)
SK (1) SK287761B6 (ru)
UA (2) UA87658C2 (ru)
WO (1) WO2001085201A2 (ru)
ZA (1) ZA200208228B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058956A2 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2435466C (en) * 2001-01-29 2012-04-03 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
CN1305529C (zh) * 2001-05-25 2007-03-21 阿雷斯贸易股份有限公司 Il－18抑制剂在治疗或预防中枢神经***损伤中的应用
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ME00548B (me) * 2002-03-22 2011-10-10 Serono Lab Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
SI1622939T1 (sl) 2003-05-13 2012-06-29 Merck Serono Sa Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PT1755642E (pt) * 2004-04-15 2010-04-20 Athera Biotechnologies Ab Anexina v para prevenção de aterotrombose e da ruptura de placas
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
RS52273B (en) 2005-06-10 2012-10-31 Ares Trading S.A. PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ru) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Метод идентификации полиморфных последовательностей 4а/4б гена эндотелиальной синтетазы оксида азота
HUE055608T2 (hu) 2013-09-05 2021-12-28 Ab2 Bio Sa IL-18-kötõ fehérje (IL-18BP) gyulladásos betegségekben
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질

Also Published As

Publication number Publication date
PL365697A1 (en) 2005-01-10
HUP0301991A3 (en) 2006-11-28
AR035640A1 (es) 2004-06-23
EP1278540B1 (en) 2008-05-14
BG107218A (bg) 2003-06-30
DE60134009D1 (de) 2008-06-26
SK287761B6 (en) 2011-09-05
MEP64008A (en) 2011-12-20
HU229375B1 (en) 2013-11-28
MXPA02010895A (es) 2003-03-27
BG65881B1 (bg) 2010-04-30
HRP20020828A2 (en) 2004-12-31
NO20025307L (no) 2002-12-18
AU2001267390B2 (en) 2005-09-22
UA87658C2 (ru) 2009-08-10
AU6739001A (en) 2001-11-20
BR0110506A (pt) 2003-04-01
EA005410B1 (ru) 2005-02-24
ME00554B (me) 2012-03-20
SK15562002A3 (sk) 2003-05-02
RS50926B (sr) 2010-08-31
CN1841066A (zh) 2006-10-04
KR100798545B1 (ko) 2008-01-28
EA007014B1 (ru) 2006-06-30
WO2001085201A2 (en) 2001-11-15
PT1278540E (pt) 2008-07-03
CZ300792B6 (cs) 2009-08-12
CY1110385T1 (el) 2015-04-29
KR20070073989A (ko) 2007-07-10
SI1278540T1 (sl) 2008-10-31
ATE395075T1 (de) 2008-05-15
JP2003532685A (ja) 2003-11-05
DK1278540T3 (da) 2008-07-21
WO2001085201A3 (en) 2002-05-10
NO329821B1 (no) 2010-12-27
ES2305082T3 (es) 2008-11-01
CZ20023644A3 (cs) 2003-03-12
UA78492C2 (en) 2007-04-10
YU82602A (sh) 2006-01-16
IL152567A0 (en) 2003-05-29
NO20025307D0 (no) 2002-11-05
CN1841066B (zh) 2012-08-29
BRPI0110506B1 (pt) 2015-05-19
ZA200208228B (en) 2005-07-27
CA2407895C (en) 2012-12-18
HK1055681A1 (en) 2004-01-21
CN1434722A (zh) 2003-08-06
KR20030016254A (ko) 2003-02-26
PL209371B1 (pl) 2011-08-31
JP5122053B2 (ja) 2013-01-16
EP1278540A2 (en) 2003-01-29
HUP0301991A2 (hu) 2003-09-29
US20040076628A1 (en) 2004-04-22
EE200200620A (et) 2004-06-15
IL152567A (en) 2010-12-30
CN1250286C (zh) 2006-04-12
BRPI0110506B8 (pt) 2021-05-25
HK1094909A1 (en) 2007-04-13
EE05056B1 (et) 2008-08-15
EA200401183A1 (ru) 2004-12-30
CA2407895A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
EA200201175A1 (ru) Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
BR0317715A (pt) Composições e processos de uso de collajolie
ES2183882T3 (es) Inhibidores de trombina.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CY1105575T1 (el) Ενωσεις αμιδιου και χρηση αυτων
HK1070008A1 (en) Combination of cytochome p 450 dependent protease inhibitors
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
WO2002028829A3 (en) Peptide deformylase inhibitors
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EA200300844A1 (ru) Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца
EA200200948A1 (ru) Лечение псориаза
SE0102921D0 (sv) Pharmaceutically useful compounds
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
RS56006B1 (sr) Korišćenje inhibitora il-18 za lečenje ili prevenciju povreda cns
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer
SE0004827D0 (sv) Therapeutic compounds
BR0209776A (pt) Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular
NO20033634L (no) GLyT-1-inhibitorer

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU